| P50 | author | Sudha Seshadri | Q28516588 |
| | Charles DeCarli | Q28516591 |
| | Ramachandran S. Vasan | Q30348351 |
| | Alexa Beiser | Q42561271 |
| | Emer R McGrath | Q57001705 |
| | Jayandra J. Himali | Q64762126 |
| P2093 | author name string | Jean E Schaffer | |
| | Daniel S Ory | |
| | Linda R Peterson | |
| | Matthew P Pase | |
| | Claudia L Satizabal | |
| | Vanessa Xanthakis | |
| | Meredith S Duncan | |
| P2860 | cites work | Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics | Q21560953 |
| | Ceramide: a common pathway for atherosclerosis? | Q24630011 |
| | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| | Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance | Q28291556 |
| | Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosis | Q30538274 |
| | Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration | Q30655992 |
| | The framingham offspring study. Design and preliminary data | Q30700098 |
| | Managing and analysing data from a large-scale study on Framingham Offspring relating brain structure to cognitive function | Q33196714 |
| | Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease | Q33670207 |
| | The role of sphingomyelin cycle metabolites in transduction of signals of cell proliferation, differentiation and death. | Q33898112 |
| | Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss | Q34106300 |
| | Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. | Q36149981 |
| | Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease | Q36604677 |
| | Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease | Q36836935 |
| | Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol | Q37057113 |
| | Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling | Q37123974 |
| | Serum sphingomyelins and ceramides are early predictors of memory impairment | Q37437931 |
| | Sphingolipids in inflammation: pathological implications and potential therapeutic targets. | Q37447464 |
| | Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency | Q37592818 |
| | Ceramide synthases as potential targets for therapeutic intervention in human diseases | Q38136056 |
| | Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. | Q39320214 |
| | The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. | Q40401973 |
| | Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide | Q40415765 |
| | Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease | Q40444820 |
| | Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid | Q42474499 |
| | Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries | Q43590614 |
| | Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis | Q44370232 |
| | Predictors of brain morphology for the men of the NHLBI twin study | Q45285482 |
| | Effect of sphingomyelinase-mediated generation of ceramide on aggregation of low-density lipoprotein | Q46451776 |
| | Blood pressure from mid- to late life and risk of incident dementia | Q46611498 |
| | Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro | Q46663698 |
| | CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance | Q46828201 |
| | Protection of C. elegans from anoxia by HYL-2 ceramide synthase | Q47995901 |
| | Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease | Q48698091 |
| | Measures of brain morphology and infarction in the framingham heart study: establishing what is normal | Q49143781 |
| | Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. | Q50917440 |
| | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. | Q55431160 |
| | Ceramide and Regulation of Vascular Tone | Q61813441 |
| | Non-parametric diffeomorphic image registration with the demons algorithm | Q62489577 |
| | Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients | Q88955111 |
| | Plasma Ceramides | Q89107277 |
| | The ceramide ratio: a predictor of cardiometabolic risk | Q89481118 |
| | Circulating IGFBP-2: a novel biomarker for incident dementia | Q92363761 |
| P433 | issue | 2 | |
| P921 | main subject | ceramides | Q424213 |
| P304 | page(s) | 160-168 | |
| P577 | publication date | 2020-01-16 | |
| P1433 | published in | Annals of clinical and translational neurology | Q27725312 |
| P1476 | title | Circulating ceramide ratios and risk of vascular brain aging and dementia | |
| P478 | volume | 7 | |